---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-26-000071"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2026-07-30T21:19:45+00:00"
generated_at: "2026-07-30T21:22:10.839123+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio gets UAE marketing authorization for ANKTIVA in bladder and lung cancers

## Summary
- UAE approved ANKTIVA for BCG-unresponsive NMIBC (CIS and papillary) and metastatic NSCLC after checkpoint failure.
- NMIBC CIS cohort (N=100): 71% complete response rate; median DoR 26.6 months, with responses beyond 54 months.
- Papillary-only cohort (N=80): 12-month disease-free survival 58.2%; 83.1% cystectomy-free at 36 months.
- NSCLC checkpoint-refractory (N=79): median OS 14.6 months; 16.2 months in patients with ALC ≥1,000.
- Authorization expands ANKTIVA's global regulatory footprint to 34 countries; validity through July 2031.

## SEC filing metadata
- accession: 0001326110-26-000071
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2026-07-30T21:19:45+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000071/0001326110-26-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000071/ibrx-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-26-000071
- JSON: https://secwatch.observer/filing/0001326110-26-000071.json
- Plain text: https://secwatch.observer/filing/0001326110-26-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.